Top News

Amgen, Merck In Collaboration Over Melanoma Treatments




Thousand Oaks-based Amgen and fellow biopharmaceuticals firm Merck said this morning that they are in an agreement to create a combination treatment for advanced melanoma. The two said they are looking to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, to treat mid to late-stage melanoma. Financial details of the collaboration were not announced by the companies.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel